Filing Details

Accession Number:
0001562180-23-004503
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-05-25 21:01:04
Reporting Period:
2023-05-24
Accepted Time:
2023-05-25 21:01:04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1517022 Akebia Therapeutics Inc. AKBA Pharmaceutical Preparations (2834) 208756903
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1669737 Michel Dahan C/O Akebia Therapeutics, Inc.
245 First Street
Cambridge MA 02142
Svp, Chief Operating Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-05-24 200,000 $0.00 669,515 No 4 A Direct
Common Stock Disposition 2023-05-25 95,478 $1.22 574,037 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to buy) Acquisiton 2023-05-24 200,000 $0.00 200,000 $0.41
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
200,000 2032-05-12 No 4 A Direct
Footnotes
  1. As previously disclosed, in May 2022, the Reporting Person was granted performance-based restricted stock units ("PSUs") pursuant to the Issuer's 2014 Incentive Plan, as amended. The PSUs vest upon the closing of a significant transaction as defined in the award agreement. On May 24, 2023, the Company entered into a License Agreement, which transaction qualified as a significant transaction and closed on May 24, 2023. As a result, all of the PSUs vested on May 24, 2023
  2. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of all of the PSUs.
  3. As previously disclosed, in May 2022, the Reporting Person was granted performance-based options (the "Options") pursuant to the Issuer's 2014 Incentive Plan, as amended. The Options vest upon the closing of a significant transaction as defined in the award agreements. On May 24, 2023, the Company entered into a License Agreement, which transaction qualified as a significant transaction and closed on May 24, 2023. As a result, all of the shares subject to the Option vested on May 24, 2023.